X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2427) 2427
Publication (53) 53
Book Chapter (14) 14
Book Review (8) 8
Dissertation (6) 6
Conference Proceeding (4) 4
Magazine Article (3) 3
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
α-glucosidase (1100) 1100
index medicus (999) 999
alpha-glucosidase (874) 874
α-glucosidase inhibitor (527) 527
glycoside hydrolase inhibitors (482) 482
chemistry, medicinal (471) 471
alpha-glucosidases - metabolism (455) 455
biochemistry & molecular biology (448) 448
food science & technology (428) 428
animals (411) 411
humans (410) 410
diabetes (358) 358
alpha-glucosidase inhibitor (341) 341
enzyme inhibitors - pharmacology (323) 323
α-amylase (322) 322
glycoside hydrolase inhibitors - pharmacology (315) 315
chemistry, applied (304) 304
glucosidase (292) 292
acarbose (284) 284
pharmacology & pharmacy (278) 278
rats (277) 277
glycoside hydrolase inhibitors - chemistry (265) 265
antioxidant (253) 253
chemistry, organic (248) 248
molecular structure (243) 243
plant extracts - pharmacology (241) 241
alpha-amylase (233) 233
male (226) 226
hypoglycemic agents - pharmacology (224) 224
plant extracts - chemistry (223) 223
enzyme inhibitors - chemistry (217) 217
α-glucosidase inhibition (217) 217
alpha-glucosidase inhibitors (214) 214
diabetes mellitus (212) 212
structure-activity relationship (208) 208
alpha-glucosidase inhibition (203) 203
derivatives (195) 195
α-glucosidase inhibitors (194) 194
alpha-glucosidases - chemistry (189) 189
inhibition (186) 186
amylase (185) 185
enzymes (185) 185
antioxidants (182) 182
kinetics (181) 181
flavonoids (174) 174
hyperglycemia (174) 174
antioxidant activity (171) 171
chemistry, multidisciplinary (170) 170
molecular docking (170) 170
in-vitro (167) 167
plant sciences (165) 165
inhibitors (160) 160
mice (159) 159
alpha-amylases - antagonists & inhibitors (150) 150
leaves (147) 147
nutrition & dietetics (146) 146
dose-response relationship, drug (143) 143
constituents (141) 141
glucose (140) 140
chemistry (137) 137
hypoglycemic agents - chemistry (131) 131
diabetes mellitus, type 2 - drug therapy (128) 128
molecular docking simulation (127) 127
extract (124) 124
extracts (119) 119
postprandial hyperglycemia (118) 118
polyphenols (115) 115
type 2 diabetes (115) 115
α‐glucosidase (114) 114
glycoside hydrolase inhibitors - isolation & purification (112) 112
saccharomyces cerevisiae - enzymology (109) 109
enzyme inhibitors - isolation & purification (108) 108
blood glucose - metabolism (105) 105
organic chemistry (105) 105
identification (104) 104
hypoglycemic agents - therapeutic use (103) 103
antioxidants - pharmacology (101) 101
biotechnology & applied microbiology (101) 101
acid (98) 98
glycoside hydrolase inhibitors - chemical synthesis (98) 98
amylases (96) 96
inhibitory concentration 50 (95) 95
α-glucosidase inhibitory activity (94) 94
insulin (91) 91
female (86) 86
antioxidants - chemistry (82) 82
biological evaluation (82) 82
alpha-amylases - metabolism (80) 80
analysis (78) 78
magnetic resonance spectroscopy (78) 78
plant leaves - chemistry (77) 77
oxidative stress (75) 75
plant extracts - isolation & purification (73) 73
agriculture, multidisciplinary (71) 71
blood glucose - drug effects (69) 69
inhibitor (69) 69
purification (69) 69
agents (68) 68
alpha-glucosidase inhibitory activity (66) 66
docking (66) 66
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 761 - 765
We assessed the efficacy and safety of sitagliptin compared with α‐glucosidase inhibitor (αGI) in 120 of Japanese patients with type 2 diabetes mellitus (T2DM)... 
type 2 diabetes | DPP‐IV inhibitor | sulphonylureas | α‐glucosidase inhibitor | randomized trial | Type 2 diabetes | Randomized trial | α-glucosidase inhibitor | Sulphonylureas | DPP-IV inhibitor | VOGLIBOSE | MONOTHERAPY | HYPERGLYCEMIA | DOUBLE-BLIND TRIAL | alpha-glucosidase inhibitor | ENDOCRINOLOGY & METABOLISM | MELLITUS | Glycated Hemoglobin A - analysis | Triazoles - adverse effects | Glycoside Hydrolase Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Pyrazines - therapeutic use | Hypoglycemia - prevention & control | 1-Deoxynojirimycin - therapeutic use | Drug Therapy, Combination - adverse effects | Inositol - therapeutic use | Inositol - adverse effects | 1-Deoxynojirimycin - analogs & derivatives | Female | 1-Deoxynojirimycin - adverse effects | Sitagliptin Phosphate | Hypoglycemia - chemically induced | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Japan | Sulfonylurea Compounds - therapeutic use | Inositol - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Gastrointestinal Agents - therapeutic use | Pyrazines - adverse effects | Aged | Gastrointestinal Agents - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | alpha-Glucosidases - metabolism | alpha-Glucosidases - chemistry
Journal Article
Journal Article
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 02/2013, Volume 27, Issue 2, pp. 148 - 155
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2010, Volume 12, Issue 7, pp. 613 - 622
Objective: To compare the efficacy and safety of sitagliptin (a dipeptidyl peptidase‐4 inhibitor) and voglibose (an α‐glucosidase inhibitor) monotherapy in... 
DPP‐4 inhibitor | incretins | sitagliptin | α‐glucosidase inhibitor | MK‐0431 | glycaemic control | voglibose | dipeptidyl peptidase‐4 inhibitor | ONO‐5435 | antihyperglycaemic agents | Incretins | Dipeptidyl peptidase-4 inhibitor | α-glucosidase inhibitor | Antihyperglycaemic agents | DPP-4 inhibitor | Voglibose | Sitagliptin | ONO-5435 | MK-0431 | Glycaemic control | alpha-glucosidase inhibitor | dipeptidyl peptidase-4 inhibitor | ACARBOSE | MELLITUS | BODY-WEIGHT | THERAPY | GLUCAGON-LIKE PEPTIDE-1 | ALPHA-GLUCOSIDASE INHIBITORS | ENDOCRINOLOGY & METABOLISM | 1,5-ANHYDROGLUCITOL | DEGRADATION | AGENTS | PEPTIDASE-4 INHIBITOR SITAGLIPTIN | Triazoles - administration & dosage | Inositol - pharmacology | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Treatment Outcome | Inositol - administration & dosage | Inositol - analogs & derivatives | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Hypoglycemic Agents - pharmacology | Triazoles - pharmacology | Asian Continental Ancestry Group | Hypoglycemic Agents - administration & dosage | Glycated Hemoglobin A | Female | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Type 2 diabetes | Medical colleges | Glycosylated hemoglobin | Clinical trials | Hypoglycemic agents | Glucose | Comparative analysis | Dextrose
Journal Article
Protein Science, ISSN 0961-8368, 08/2018, Volume 27, Issue 8, pp. 1498 - 1508
Carbohydrate hydrolyzing α‐glucosidases are commonly found in microorganisms present in the human intestine microbiome. We have previously reported crystal... 
α‐glucosidase | α‐glucosidase inhibitor | substrate/inhibitor selection | acarbose | antidiabetic drug | voglibose | miglitol | human gut microbiome | α-glucosidase | α-glucosidase inhibitor | SITE | ANTIBIOTICS | MUTAGENESIS | alpha-glucosidase inhibitor | BIOCHEMISTRY & MOLECULAR BIOLOGY | TOXICITY | HUMAN MICROBIOME PROJECT | BIOFUELS | alpha-glucosidase | METABOLISM | inhibitor selection | DRUGS | INTESTINAL MALTASE-GLUCOAMYLASE | substrate | Hypoglycemic Agents - pharmacokinetics | Hypoglycemic Agents - metabolism | Glycoside Hydrolase Inhibitors - metabolism | Humans | Bacterial Proteins - chemistry | Models, Molecular | Gastrointestinal Microbiome - physiology | Hypoglycemic Agents - chemistry | Glycoside Hydrolase Inhibitors - chemistry | Inositol - analogs & derivatives | Glycoside Hydrolase Inhibitors - pharmacokinetics | Protein Binding | 1-Deoxynojirimycin - analogs & derivatives | Bacterial Proteins - metabolism | Ruminococcus - enzymology | alpha-Glucosidases - metabolism | alpha-Glucosidases - chemistry | Binding | Carbohydrates | Acarbose | Digestive system | Diabetes mellitus | Miglitol | Microbiomes | Homology | Glucosidase | Drug development | Substrates | Microorganisms | Inhibitors | Intestine | Substrate preferences | Bacteria | Glucoamylase | Digestive tract | Crystal structure | BASIC BIOLOGICAL SCIENCES | anti-diabetic drug | Full‐Length Papers
Journal Article
Process Biochemistry, ISSN 1359-5113, 02/2018, Volume 65, pp. 228 - 232
[Display omitted] •New α-glucosidase inhibitors (aGIs) were isolated and identified from fermented Nutrient Broth.•All the isolated compounds are... 
α–glucosidase inhibitor | Diabetes | Microbial conversion | Paenibacillus sp | ENGINEERING, CHEMICAL | NEWLY ISOLATED STRAIN | 1-DEOXYNOJIRIMYCIN | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | alpha-glucosidase inhibitor | BIOCHEMISTRY & MOLECULAR BIOLOGY | PURIFICATION | FERMENTATION | IDENTIFICATION
Journal Article
Journal Article